Caplin Point Laboratories share news and announcements
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,222.00down ₹27.10 (1.20%)BSE ₹2,222.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,249.10.
52-week range of traded prices to 23 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,890 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 76,90447.0% delivered
Caplin Point Laboratories share news and announcements
496 announcements, routine notices left out, newest first. Page 10 of 10.
Oct 2015
Sep 2015
Aug 2015
Jul 2015
Jun 2015
May 2015
Apr 2015
Mar 2015
Feb 2015
Jan 2015
Dec 2014
22 Dec · Disclosure of Voting Pattern - Clause 35A
Nov 2014
24 Nov · Meeting
Register of Member and Share Transfer Books of the Company will remain closed from December 13, 2014 to December 18, 2014 (both days inclusive) for the purpose of Annual General Meeting and also towards payment of Final Dividend subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company to be held on December 18, 2014.3 Nov · Board meeting
A) to consider and approve inter-alia, the Un-Audited Financial Results of the Company for the Quarter ended 30th September, 2014 b) to consider and fix date, time and venue for the Annual General Meeting (AGM) of the Company and to fix the Book Closure date of Register of Members and Share Transfer Books, towards Final Dividend for FY 2013-14 and AGM.
Aug 2014
26 Aug · Management
Mr. Sridhar Ganesan, an Independent Director in the Board of the Company has resigned with effect from August 25, 2014, as the Board has requested Mr. Sridhar Ganesan to involve in the affairs of the Company on a whole time basis. Hence, Mr. Sridhar Ganesan would be functioning as a Whole Time Director of the Company with effect from August 25, 2014.26 Aug · Management
Dr. K C John is appointed as an Independent Director by the Board of the Company with effect from 25th August, 2014.25 Aug · Dividend
Board of Directors of the Company at their meeting held on August 25, 2014 has considered and approved inter-alia; Recommendation of final dividend of Rs.4.00/-(Rupees Four Only) per share (40%) on the equity capital of Rs. 10/- each for the year ended June 30, 2014 subject to the approval of the Shareholders in the ensuring Annual General Meeting.
Jul 2014